Sebastian Aguirre

Company: Carbon Biosciences

Job title: Co-Founder, Vice President & Head of Platform Development

Seminars:

Extending the Reach of Genetic Medicine Through Next-Generation Parvovirus Vector Technology 11:30 am

• A comparison of LNPs and AAVs reveals key differences in immunogenicity and toxicity, suggesting potential benefits of combined use • Improved targeting and uptake strategies aim to mitigate immune responses and toxicity in metabolic liver diseases • Overcoming delivery challenges, for LNPs to be optimized for more effective transport of therapies to liver cellsRead more

day: Day 1- Translation 1